시장보고서
상품코드
1944482

약물 탈감작 시장 : 종류별, 최종사용자별, 판매 채널별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Drug Desensitization Market, By Type, By End-Users, By Sales Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 328 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

약물 탈감작 시장 규모는 2024년에 6억 210만 달러로 평가되었으며, 2025년부터 2032년까지 CAGR 8.07%로 확대될 전망입니다.

약물 탈감작 시장에는 알려진 과민증이나 알레르기 반응이 있는 환자에서 중요한 약물에 대한 내성을 일시적으로 증가시키는 것을 목표로 하는 치료적 개입과 체계화된 임상 프로토콜이 포함됩니다. 이를 통해 통제된 의료 환경에서 치료를 지속할 수 있습니다. 약물 알레르기의 유병률 증가와 항생제, 화학요법제, 생물학적 제제 등 중증 및 생명을 위협하는 질환을 치료하기 위해 필수적인 1차 치료제에 대한 의존도가 높아지면서 시장 성장을 견인하고 있습니다. 중요한 시장 트렌드로는 첨단 진단 도구와 환자 모니터링 기술을 기반으로 한 개인화된 프로토콜 기반의 감작 전략으로 전환하는 것을 들 수 있습니다. 그러나 고도로 훈련된 의료진의 필요성, 집중적인 임상 모니터링, 높은 치료 비용 등이 주요 제약요인으로 작용하고 있습니다. 이러한 한계에도 불구하고, 임상의의 인식 개선과 생물학적 제제 및 종양 치료의 사용 증가는 병원 및 전문 의료 시설에서 표준화된 탈감작 프로그램을 광범위하게 도입할 수 있는 큰 기회를 제공하고 있습니다.

약물 탈감작의 시장 역학

약물 과민반응의 증가 추세

약물 과민반응의 발생률 증가는 약물 탈감작 요법에 대한 세계 수요를 견인하는 주요 요인입니다. 제약 업계가 새로운 치료 영역으로 확장하고 있는 가운데, 항생제, 화학요법제, 생물학적 제제를 포함한 필수 의약품에 대한 면역 매개 부작용을 경험하는 환자 수가 증가하고 있습니다. 이러한 과민반응은 경미한 피부 발진부터 생명을 위협하는 심각한 알레르기 반응까지 그 심각성이 매우 다양하며, 효과적이고 지속적인 치료에 심각한 문제를 제기하고 있습니다. 2023년 3월 '알레르기 질환의 병태와 치료 개입에 대한 시사점' 총설에 따르면, 약물 과민반응은 전체 유해 약물 반응의 약 5-10%를 차지하며, 전 세계 인구의 약 7-10%에게 영향을 미칩니다. 자가보고에 의한 약물 알레르기는 약 8%의 개인에게 발생하지만, 확정 진단 사례는 훨씬 적은 상황입니다. 소아 집단에서는 과민반응이 의심되는 사례가 1-2%를 차지하며, 확정 진단 사례는 약 0.05%를 기록할 것으로 예상됩니다. 항생제는 여전히 가장 흔한 유발인자이며, 스티븐스존슨 증후군을 포함한 심각한 반응의 약 30%를 유발합니다.

약물 탈감작 시장 : 세분화 분석

세계 시장의 시장 세분화는 유형, 최종사용자, 판매 채널, 지역을 기준으로 이루어집니다.

유형별로는 환자 중심의 다양한 이점을 가진 설하 면역요법(SLIT)이 현재 세계 약물 탈감작 시장을 주도하고 있으며, 2025년까지 66.1%의 점유율을 차지할 것으로 예상됩니다. 환자에게 가장 중요한 장점은 알레르겐 추출물과 치료제를 혀 밑으로 투여한다는 점에 있습니다. 환자 스스로 집에서 쉽고 편안하게 치료할 수 있어 잦은 병원 방문의 번거로움을 줄일 수 있습니다.

2023년 10월, 미국 알레르기-천식-면역학회(AAAAI)는 설하 면역요법(SLIT)을 통해 땅콩 알레르기가 있는 소아에서 3년 동안 60%의 탈감작과 48%의 완화를 달성했다고 보고했습니다. 연구에 따르면, 유아기의 조기 개입이 약물 탈감작과 장기적인 알레르기 완화를 촉진하는 중요한 요소라는 것이 밝혀졌습니다.

병원 및 전문 알레르기 클리닉은 전 세계 약물 탈감작 시장에서 가장 큰 최종사용자입니다. 이러한 장점은 통제된 의료 환경에서 고도의 진단 능력, 전문적인 임상 지식 및 다직종 환자 관리를 통합할 수 있다는 점에서 비롯됩니다. 이들 시설은 개별화된 투여 프로토콜, 지속적인 환자 모니터링, 면역학 및 알레르기 전문의의 엄격한 감독을 통해 복잡한 약물 탈감작 절차를 시행할 수 있는 독자적인 시스템을 갖추고 있어 안전하고 정밀하며 근거에 기반한 치료를 보장합니다. 이 분야에서 병원과 전문 클리닉의 중요성은 첨단 감작 치료의 규제 승인으로 강조되고 있습니다. 예를 들어, 2024년 2월 미국 식품의약국(FDA)은 젠젠텍과 노바티스가 개발한 졸리아(오말리주맙)를 실수로 여러 식품에 노출된 후 알레르기 반응을 감소시키는 것으로 입증된 최초의 약품으로 승인했습니다. 이번 승인은 IgE 매개 식품 알레르기가 있는 1세 이상의 소아 및 성인에 대한 적용 범위를 확대하는 것으로, 고도의 탈감작 치료를 시행하고 관리하는 데 있어 병원 및 전문 클리닉의 중요한 역할을 강조하는 것입니다.

약물 탈감작 시장 - 지역별 분석

2025년 세계 약물 탈감작 시장에서 북미는 중요한 지역을 차지하고 있습니다. 이는 고도로 발달된 의료 인프라, 제약 및 생명공학 기업의 높은 집중도, 알레르기 관리 및 면역 관용 치료의 혁신을 촉진하는 정부 지원 정책에 힘입은 바 큽니다. 이 지역은 또한 연구개발에 대한 공공 및 민간 투자가 크게 증가하고 있으며, 이는 치료법의 발전과 임상 도입을 지속적으로 촉진하고 있습니다. 예를 들어, 2025년 9월 미국 소재 바이오 제약기업인 ARS 파마슈티컬스(ARS Pharmaceuticals)는 알레르기 반응 및 아나필락시스의 응급 치료를 위한 세계 최초이자 유일한 바늘을 사용하지 않는 에피네프린 비강 점비제 '네피'에 대해 일본 규제 당국의 승인을 획득했습니다. 허가를 취득하였습니다. 알프레사 홀딩스와의 공동 개발로 탄생한 이 제품은 알프레사 홀딩스가 일본 내 판매를 담당하며, 2025년 4분기부터 성인 및 체중 15kg 이상의 소아 환자를 대상으로 공급을 시작할 예정입니다.

미국 약물 탈감작 시장 - 국가별 분석

미국의 약물 탈감작 시장은 연구개발에 대한 막대한 투자, 선진화된 의료 인프라, 환자의 높은 약물 및 식품 과민증 유병률에 힘입어 세계 최대 규모를 유지하고 있습니다. Regeneron Pharmaceuticals 및 Horizon Therapeutics와 같은 주요 제약회사의 강력한 존재감과 전문 알레르기 치료 센터의 설립으로 미국 전역에서 첨단 탈감작 프로토콜의 채택이 가속화되고 있습니다. 예를 들어, 2023년 9월 네슬레는 땅콩 알레르기 치료제 '파르포르지아'를 알레르겐 면역치료 및 약물 탈감작 분야에서 높은 명성을 얻고 있는 미국 기업 Stallergenes Greer에 매각했습니다. 미국 FDA가 땅콩 알레르기에 대해 승인한 최초의 경구용 치료제인 파르포르시아는 2020년 네슬레가 21억 달러에 인수했지만, 상업적 보급은 제한적이었습니다. 이번 인수를 통해 스타라제네시스 글리아는 호흡기 알레르기와 음식물 알레르기 치료제를 모두 제공하는 최초의 회사가 되었으며, 네슬레는 소화기 치료에 전략적 우선순위를 재조정할 수 있게 되었습니다.

목차

제1장 약물 탈감작 시장 개요

제2장 주요 요약

제3장 약물 탈감작 주요 시장 동향

제4장 약물 탈감작 업계 조사

제5장 약물 탈감작 시장 : 높아지는 지정학적 긴장의 영향

제6장 약물 탈감작 시장 시장 구도

제7장 약물 탈감작 시장 : 종류별

제8장 약물 탈감작 시장 : 최종사용자별

제9장 약물 탈감작 시장 : 판매 채널별

제10장 약물 탈감작 시장 : 지역별

제11장 주요 벤더 분석 : 약물 탈감작 산업

제12장 AnalystView의 전방위적 분석

KSM

The Drug Desensitization Market size was valued at US$ 602.10 Million in 2024, expanding at a CAGR of 8.07% from 2025 to 2032.

The drug desensitization market includes therapeutic interventions and structured clinical protocols aimed at temporarily increasing patient tolerance to critical medications in people with known hypersensitivity or allergic reactions, allowing them to continue receiving treatment in controlled healthcare settings. The growing prevalence of drug allergies, as well as the increasing reliance on essential first-line therapies such as antibiotics, chemotherapy agents, and biologics for the treatment of serious and life-threatening conditions, are driving market growth. A significant market trend is the shift toward personalized, protocol-based desensitization strategies that are supported by advanced diagnostic tools and patient monitoring technologies. Nonetheless, the requirement for highly trained medical personnel, intensive clinical oversight, and the associated high treatment costs serve as a major constraint. Despite these limitations, rising clinician awareness and the increasing use of biologics and oncology treatments present significant opportunities for the widespread implementation of standardized desensitization programs in hospitals and specialty care settings.

Drug Desensitization Market- Market Dynamics

Rising Prevalence of Drug Hypersensitivity Reactions

The increasing incidence of drug hypersensitivity reactions is a major factor driving global demand for drug desensitization therapies. As the pharmaceutical industry continues to expand into new therapeutic areas, a growing number of patients are experiencing immune-mediated adverse reactions to essential medications, including antibiotics, chemotherapeutic agents, and biologics. These hypersensitivity reactions vary widely in severity, ranging from mild skin rashes to severe, life-threatening allergic responses, posing significant challenges to effective and continuous treatment. According to a March 2023 review article titled "Pathogenesis of Allergic Diseases and Implications for Therapeutic Interventions," drug hypersensitivity reactions account for approximately 5-10% of all adverse drug reactions and affect nearly 7-10% of the global population. While self-reported drug allergies occur in about 8% of individuals, confirmed cases are considerably lower. In pediatric populations, suspected hypersensitivity reactions affect 1-2%, with confirmed cases around 0.05%. Antibiotics remain the most common triggers, responsible for nearly 30% of severe reactions, including Stevens-Johnson syndrome.

Drug Desensitization Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Type, End-Users, Sales Channel, and Region.

In terms of types, Sublingual Immunotherapy (SLIT), with its numerous patient-centered benefits, is now the market leader in global drug desensitization, accounting for 66.1% by 2025. The most significant factor in the patient-friendly benefits is the administration of allergenic extracts or therapeutic agents under the tongue, which patients perform themselves, providing an easy and comfortable way of treatment at home while avoiding the hassle of frequent clinic visits.

In October 2023, the American Academy of Allergy, Asthma, and Immunology (AAAAI) reported that sublingual immunotherapy (SLIT) resulted in 60% desensitization and 48% remission in peanut-allergic children over three years. According to the research, early childhood intervention is a critical factor in facilitating drug desensitization and long-term allergy remission.

Hospitals and specialized allergy clinics are the largest end-users in the global drug desensitization market. This dominance stems from their ability to combine advanced diagnostic capabilities, specialized clinical expertise, and multidisciplinary patient management in controlled healthcare settings. These facilities are uniquely equipped to perform complex drug desensitization procedures by utilizing individualized dosing protocols, continuous patient monitoring, and close supervision by immunology and allergy specialists, ensuring safe, precise, and evidence-based care. The importance of hospitals and specialty clinics in this segment is emphasized by regulatory approvals of advanced desensitization therapies. For example, in February 2024, the United States Food and Drug Administration approved Xolair (omalizumab), developed by Genentech and Novartis, as the first medication shown to reduce allergic reactions to multiple foods after accidental exposure. This approval, which extends the use to adults and children aged one year and older with IgE-mediated food allergies, emphasizes the critical role of hospital-based and specialty clinics in administering and managing advanced desensitization treatments.

Drug Desensitization Market- Geographical Insights

North America represents a significant region in the global drug desensitization market in 2025, supported by its highly advanced healthcare infrastructure, strong concentration of pharmaceutical and biotechnology companies, and supportive government policies that promote innovation in allergy management and immune tolerance therapies. The region also benefits from substantial public and private investments in research and development, which continue to drive therapeutic advancements and clinical adoption. For example, in September 2025, ARS Pharmaceuticals, a U.S.-based biopharmaceutical company, received regulatory approval in Japan for Neffy, the first and only needle-free epinephrine nasal spray indicated for the emergency treatment of allergic reactions and anaphylaxis. Developed in collaboration with Alfresa Holdings, which will commercialize the product in Japan, Neffy is expected to be available in the fourth quarter of 2025 for adults and pediatric patients weighing more than 15 kilograms.

United States Drug Desensitization Market- Country Insights

The U.S. drug desensitization market remains the largest globally, supported by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of drug and food sensitivities among patients. The strong presence of leading pharmaceutical companies such as Regeneron Pharmaceuticals and Horizon Therapeutics, along with well-established specialized allergy treatment centers, is accelerating the adoption of advanced desensitization protocols across the country. For instance, in September 2023, Nestle divested its peanut allergy treatment Palforzia to U.S.-based Stallergenes Greer, a recognized leader in allergen immunotherapy and drug desensitization. Palforzia, the first oral therapy approved by the U.S. FDA for peanut allergy, was originally acquired by Nestle in 2020 for USD 2.1 billion but experienced limited commercial uptake. This acquisition positioned Stallergenes Greer as the first company to offer therapies for both respiratory and food allergies, while enabling Nestle to refocus its strategic priorities on gastrointestinal treatments.

Drug Desensitization Market- Competitive Landscape:

The drug desensitization market is moderately consolidated, with established pharmaceutical companies, specialized allergy therapy providers, and emerging biotech firms specializing in immunology and hypersensitivity management. Market participants compete by developing new products, expanding clinical indications, and forming strategic alliances with hospitals and specialty allergy clinics. Companies are increasing their investment in research and development to improve desensitization protocols, improve patient safety, and broaden applications for food, drug, and biologic allergies. Regulatory approvals and acquisitions remain critical strategies for improving market positioning and expanding product portfolios. Leading players in the market include ALK-Abello A/S, HollisterStier Allergy (Jubilant Pharma), All Cure Pharma Pvt Ltd, and Allergopharma GmbH and Co KG. They use clinical expertise and global distribution networks to maintain a competitive edge and drive market growth.

Recent Developments:

In February 2025, ALK-AbellA/S, a Danish-based global specialty pharmaceutical company specializing in allergy immunotherapy and allergic asthma, has received FDA approval for its DACTRAtablet to treat house dust mite-induced allergic rhinitis in children aged five to eleven. This expands its previous approval for patients aged twelve to sixty-five and strengthens ALK's position in drug desensitization therapy.

In January 2025, Stallergenes Greer, a Swiss biopharmaceutical company that specializes in allergen immunotherapy, has received European Commission approval to extend Palforzia for the treatment of toddlers aged one to three who have a confirmed peanut allergy. Palforzia, the first oral drug desensitization therapy approved by the EMA and the FDA for this age group, promotes tolerance to peanut allergens and reduces the risk of severe allergic reactions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG DESENSITIZATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • IDEXX Laboratories Inc
  • ALK-Abello A/S
  • HollisterStier Allergy (Jubilant Pharma)
  • All Cure Pharma Pvt Ltd
  • Allergopharma GmbH and Co KG
  • HAL Allergy Group
  • LETI Pharma
  • Torii Pharmaceutical Co Ltd
  • Inmunotek S.L.
  • Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
  • DBV Technologies SA
  • Prota Therapeutics Pty Ltd
  • Stallergenes Greer
  • Allergy Therapeutics pIc
  • Aimmune Therapeutics Inc
  • Others

GLOBAL DRUG DESENSITIZATION MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
  • Other emerging immunotherapy delivery methods

GLOBAL DRUG DESENSITIZATION MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

  • Outpatient treatment centers
  • Hospitals and specialty allergy clinics
  • Homecare settings
  • Others

GLOBAL DRUG DESENSITIZATION MARKET, BY SALES CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Channel
  • Offline Channel

GLOBAL DRUG DESENSITIZATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Drug Desensitization Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Drug Desensitization Market Snippet by Type
    • 2.1.2. Drug Desensitization Market Snippet by End-Users
    • 2.1.3. Drug Desensitization Market Snippet by Sales Channel
    • 2.1.4. Drug Desensitization Market Snippet by Country
    • 2.1.5. Drug Desensitization Market Snippet by Region
  • 2.2. Competitive Insights

3. Drug Desensitization Key Market Trends

  • 3.1. Drug Desensitization Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Drug Desensitization Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Drug Desensitization Market Opportunities
  • 3.4. Drug Desensitization Market Future Trends

4. Drug Desensitization Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Drug Desensitization Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Drug Desensitization Market Landscape

  • 6.1. Drug Desensitization Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Drug Desensitization Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Subcutaneous Immunotherapy (SCIT)
    • 7.1.3. Sublingual Immunotherapy (SLIT)
    • 7.1.4. Other emerging immunotherapy delivery methods

8. Drug Desensitization Market - By End-Users

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
    • 8.1.2. Outpatient treatment centers
    • 8.1.3. Hospitals and specialty allergy clinics
    • 8.1.4. Homecare settings
    • 8.1.5. Others

9. Drug Desensitization Market - By Sales Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Sales Channel, 2024 & 2032 (%)
    • 9.1.2. Online Channel
    • 9.1.3. Offline Channel

10. Drug Desensitization Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Drug Desensitization Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Drug Desensitization Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Drug Desensitization Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Drug Desensitization Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Drug Desensitization Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Drug Desensitization Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. IDEXX Laboratories Inc
    • 11.2.2. ALK-Abello A/S
    • 11.2.3. HollisterStier Allergy (Jubilant Pharma)
    • 11.2.4. All Cure Pharma Pvt Ltd
    • 11.2.5. Allergopharma GmbH and Co KG
    • 11.2.6. HAL Allergy Group
    • 11.2.7. LETI Pharma
    • 11.2.8. Torii Pharmaceutical Co Ltd
    • 11.2.9. Inmunotek S.L.
    • 11.2.10. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
    • 11.2.11. DBV Technologies SA
    • 11.2.12. Prota Therapeutics Pty Ltd
    • 11.2.13. Stallergenes Greer
    • 11.2.14. Allergy Therapeutics pIc
    • 11.2.15. Aimmune Therapeutics Inc
    • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제